Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sramek

Showing results (11-20 of 156) with videos related to

Pageof 16
Sort By:
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Ethnicity and antidepressant responseJ J Sramek, E H Pi
Alzheimer Disease and Associated Disorders|January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"N R Cutler, J J Sramek
Clinical Neuropharmacology|January 1, 1986
Plasma neuroleptic concentration: in search of a therapeutic windowS Potkin, R Hahn, J Sramek
Drugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R Cutler
Archives of Biochemistry and Biophysics|November 1, 1975
Escherichia coli coenzyme A-transferase: kinetics, catalytic pathway and structureS J Sramek, F E Frerman
The New England Journal of Medicine|March 18, 1993
Tacrine in Alzheimer's diseaseN R Cutler, J J Sramek
The New England Journal of Medicine|January 5, 1995
The use of placebo controlsJ J Sramek, N R Cutler
American Journal of Ophthalmology|May 15, 1992
Trauma-induced Acinetobacter lwoffi endophthalmitisT S Melki, S J Sramek
Archives of Biochemistry and Biophysics|November 1, 1975
Purification and properties of Escherichia coli coenzyme A-transferaseS J Sramek, F E Frerman
Journal of Clinical Pharmacology|November 15, 2000
Investigator perspective on MTD: practical application of an MTD definition--has it accelerated development?N R Cutler, J J Sramek
Pageof 16

Showing results (11-20 of 156) with videos related to

Sort By:
Pageof 16
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Ethnicity and antidepressant responseJ J Sramek, E H Pi
Alzheimer Disease and Associated Disorders|January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"N R Cutler, J J Sramek
Clinical Neuropharmacology|January 1, 1986
Plasma neuroleptic concentration: in search of a therapeutic windowS Potkin, R Hahn, J Sramek
Drugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R Cutler
Archives of Biochemistry and Biophysics|November 1, 1975
Escherichia coli coenzyme A-transferase: kinetics, catalytic pathway and structureS J Sramek, F E Frerman
The New England Journal of Medicine|March 18, 1993
Tacrine in Alzheimer's diseaseN R Cutler, J J Sramek
The New England Journal of Medicine|January 5, 1995
The use of placebo controlsJ J Sramek, N R Cutler
American Journal of Ophthalmology|May 15, 1992
Trauma-induced Acinetobacter lwoffi endophthalmitisT S Melki, S J Sramek
Archives of Biochemistry and Biophysics|November 1, 1975
Purification and properties of Escherichia coli coenzyme A-transferaseS J Sramek, F E Frerman
Journal of Clinical Pharmacology|November 15, 2000
Investigator perspective on MTD: practical application of an MTD definition--has it accelerated development?N R Cutler, J J Sramek
Pageof 16